| Institution: | 1. Division of Tuberculosis Vaccines, National Institutes for Food and Drug Control, Beijing 102629, China;2. Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China;3. Centre for Biologicals Evaluation, Biologics and Genetic Therapies Directorate, Health Canada, Ottawa, Ontario, Canada;1. State Key Laboratory for Infectious Disease Prevention and Control, National Institute for Communicable Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Chinese Center for Disease Control and Prevention, Beijing, China;2. State Key Laboratory of Agrobiotechnology, Department of Microbiology and Immunology, College of Biological Sciences, China Agricultural University, Beijing 100193, China;3. Beijing Center for Diseases Prevention and Control, Beijing 100013, China;1. St George’s Medical School, University of London, London SW17 0RE, UK;2. Lionex GmbH, Braunschweig, Germany;3. Karolinska Institute, Stockholm, Sweden;1. School of Health Sciences (PPSK), Universiti Sains Malaysia (USM), 16150 Kubang Kerian, Kelantan, Malaysia;2. Rutgers New Jersey Medical School, Public Health Research Institute, Newark, NJ, USA;3. Department of Biomedical Sciences and Therapeutic, Faculty of Medicine and Health Sciences (FPSK), Universiti Malaysia Sabah (UMS), Sabah, Malaysia;4. Institute of Biotechnology, INTA, Buenos Aires, Argentina;5. Finlay Institute of Vaccines, La Habana, Cuba;1. Animal Biosafety Level III Laboratory at the Center for Animal Experiment, Wuhan University School of Medicine, Wuhan, Hubei, PR China;2. Aeras, Rockville, MD, USA;3. Department of Pathology and Laboratory Medicine, Temple University School of Medicine, Philadelphia, PA, USA |
